Bumetanide analog(NeuroPro Therapeutics, Inc.)(Bumetanide analog(NeuroPro Therapeutics, Inc.)) - 药物靶点：NKCC2_在研适应症：全身性癫痫，癫痫发作，反射性癫痫_专利_临床

概要

基本信息

药物类型

小分子化药

别名

bumetanide analog(NeuroPro Therapeutics, Inc.)、NPT 2042、NPT-2042

+ [1]

靶点

NKCC2

作用方式

抑制剂

作用机制

NKCC2抑制剂(钠钾氯协同转运蛋白-2抑制剂)

治疗领域

神经系统疾病其他疾病

在研适应症

全身性癫痫癫痫发作反射性癫痫+ [2]

非在研适应症-

原研机构

NeuroPro Therapeutics, Inc.

在研机构

NeuroPro Therapeutics, Inc.

非在研机构-

权益机构-

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

4

项与 Bumetanide analog(NeuroPro Therapeutics, Inc.) 相关的临床试验

NCT07222878

/ Recruiting临床1期

A Single-center, Open-label, Single-dose, Three-period, Fixed Sequence Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules Compared to the Original Formulation of NPT 2042 Soft-Gelatin Capsules Administered Orally to Healthy Adult Participants With Co-administered Agent

A Single-center, Open-label, Single-dose, Three-period, Fixed Sequence Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules

开始日期2025-09-29

申办/合作机构

NeuroPro Therapeutics, Inc.

NCT06769659

/ Recruiting临床2期

A Single-center, Double-blind, Placebo-controlled Crossover Study Evaluating NPT 2042 Versus Placebo in Subjects Aged 16-75 Years With Genetic Generalized Epilepsy (GGE) and Absence Seizures

This study will compare the effect of NPT 2042 and placebo in subjects with GGE on the frequency and duration of electroencephalographic absence seizures, separated by a 14-day washout period. The study will be a single-center, double-blind, crossover study with subjects receiving either NPT 2042 80 mg BID orally or matching placebo BID in each of two treatment periods.

开始日期2025-03-11

申办/合作机构

NeuroPro Therapeutics, Inc.

NCT06525649

/ Completed临床1期

A Double Blind, Randomized, Cross-over Study Examining the Suppression of the Photoparoxysmal EEG Response With NPT 2042

A double-blind, placebo-controlled, crossover trial to investigate the PPR of approximately 5 subjects with a known stable PPR on EEG, using 2 doses of NPT 2042 compared to placebo.

开始日期2024-08-21

申办/合作机构

NeuroPro Therapeutics, Inc.

100 项与 Bumetanide analog(NeuroPro Therapeutics, Inc.) 相关的临床结果

登录后查看更多信息

100 项与 Bumetanide analog(NeuroPro Therapeutics, Inc.) 相关的转化医学

登录后查看更多信息

100 项与 Bumetanide analog(NeuroPro Therapeutics, Inc.) 相关的专利（医药）

登录后查看更多信息

100 项与 Bumetanide analog(NeuroPro Therapeutics, Inc.) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
全身性癫痫	临床2期	美国	NeuroPro Therapeutics, Inc.	2025-03-11
癫痫发作	临床2期	美国	NeuroPro Therapeutics, Inc.	2025-03-11
反射性癫痫	临床1期	美国	NeuroPro Therapeutics, Inc.	2024-08-21
阿尔茨海默症	临床1期	美国	NeuroPro Therapeutics, Inc.	2022-10-20
耐药性癫痫	临床1期	美国	NeuroPro Therapeutics, Inc.	2022-10-20